Form 4: Halozyme Therapeutics SVP, Chief Technical Officer, Michael J. LaBarre, Executes Option Exercises and Stock Sales

Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael J. LaBarre, the SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock on September 17 and 18, 2024.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2023.
• On both September 17 and 18, 2024, LaBarre exercised options to purchase 10,000 shares of common stock at a price of $16.65 per share.
• Contemporaneously, LaBarre sold shares of common stock on the open market.
• On September 17, 2024, 10,000 shares were sold at a weighted average price of $62.878, with prices ranging from $62.585 to $63.275.
• On September 18, 2024, 7,963 shares were sold at a weighted average price of $61.891 (ranging from $61.40 to $62.395) and 2,037 shares were sold at a weighted average price of $62.581 (ranging from $62.41 to $62.67).
• Following these transactions, LaBarre directly owns 173,756 shares of common stock and options to purchase 11,861 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives and their potential views on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates